Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

330 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Single-Run HPLC-MS Multiplex Assay for Therapeutic Drug Monitoring of Relevant First- and Second-Line Antibiotics in the Treatment of Drug-Resistant Tuberculosis.
Köhler N, Karaköse H, Grobbel HP, Hillemann D, Andres S, König C, Kalsdorf B, Brehm TT, Böttcher L, Friesen I, Hoffmann H, Strelec D, Schaub D, Peloquin CA, Schmiedel S, Decosterd LA, Choong E, Wicha SG, Aarnoutse RE, Lange C, Sánchez Carballo PM. Köhler N, et al. Among authors: andres s. Pharmaceutics. 2023 Oct 27;15(11):2543. doi: 10.3390/pharmaceutics15112543. Pharmaceutics. 2023. PMID: 38004523 Free PMC article.
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
Olaru ID, Heyckendorf J, Andres S, Kalsdorf B, Lange C. Olaru ID, et al. Among authors: andres s. Eur Respir J. 2017 May 21;49(5):1700742. doi: 10.1183/13993003.00742-2017. Print 2017 May. Eur Respir J. 2017. PMID: 28529207 Free article. No abstract available.
What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis.
Heyckendorf J, Andres S, Köser CU, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M. Heyckendorf J, et al. Among authors: andres s. Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01550-17. doi: 10.1128/AAC.01550-17. Print 2018 Feb. Antimicrob Agents Chemother. 2018. PMID: 29133554 Free PMC article.
Reply to Dookie et al., "Whole-Genome Sequencing To Guide the Selection of Treatment for Drug-Resistant Tuberculosis".
Köser CU, Heyckendorf J, Andres S, Olaru ID, Schön T, Sturegård E, Beckert P, Schleusener V, Kohl TA, Hillemann D, Moradigaravand D, Parkhill J, Peacock SJ, Niemann S, Lange C, Merker M. Köser CU, et al. Among authors: andres s. Antimicrob Agents Chemother. 2018 Jul 27;62(8):e00616-18. doi: 10.1128/AAC.00616-18. Print 2018 Aug. Antimicrob Agents Chemother. 2018. PMID: 30054377 Free PMC article. No abstract available.
Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
Andres S, Merker M, Heyckendorf J, Kalsdorf B, Rumetshofer R, Indra A, Hofmann-Thiel S, Hoffmann H, Lange C, Niemann S, Maurer FP. Andres S, et al. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1564-1568. doi: 10.1164/rccm.201909-1819LE. Am J Respir Crit Care Med. 2020. PMID: 32053752 No abstract available.
Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing.
Grobbel HP, Merker M, Köhler N, Andres S, Hoffmann H, Heyckendorf J, Reimann M, Barilar I, Dreyer V, Hillemann D, Kalsdorf B, Kohl TA, Sanchez Carballo P, Schaub D, Todt K, Utpatel C, Maurer FP, Lange C, Niemann S. Grobbel HP, et al. Among authors: andres s. Clin Infect Dis. 2021 Oct 5;73(7):1194-1202. doi: 10.1093/cid/ciab359. Clin Infect Dis. 2021. PMID: 33900387 Free PMC article.
330 results